Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de la Victoria (21)

2024

  1. The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers

    Journal of Clinical Investigation, Vol. 134, Núm. 8

2023

  1. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

    Clinical Microbiology and Infection, Vol. 29, Núm. 1, pp. 85-93

2022

  1. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

2021

  1. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

    Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

  3. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study

    Journal of the International Association of Providers of AIDS Care, Vol. 17

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

  2. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

  2. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2014

  1. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting

    HIV Medicine, Vol. 15, Núm. 7, pp. 417-424

  2. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  3. Predictors of early mortality in very elderly patients with bacteremia: A prospective multicenter cohort

    International Journal of Infectious Diseases, Vol. 26, pp. 83-87

  4. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2013

  1. Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: A prospective cohort study

    BMC Infectious Diseases, Vol. 13, Núm. 1

2012

  1. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 1, pp. 472-478

2009

  1. Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: Effect of hepatitis virus co-infection and pre-existing fibrosis

    Journal of Antimicrobial Chemotherapy, Vol. 63, Núm. 1, pp. 178-183

2008

  1. Efficacy of pegylated interferon plus ribavirin treatment in HIV/ hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 6, pp. 1365-1373